Monte Rosa Therapeutics Inc

NASDAQ:GLUE

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. The company focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.